Journal
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS
Volume 60, Issue 9, Pages 401-409Publisher
WILEY
DOI: 10.1002/jlcr.3516
Keywords
CRPC; deuterated drug; enzalutamide; LNCaP/AR xenograft; PK/PD
Funding
- National Natural Science Foundation of China [81472418 81472418]
- Hinova Pharmaceuticals Inc
Ask authors/readers for more resources
Enzalutamide, a second-generation antiandrogen, has been developed for the treatment of castration-resistance prostate cancer. We synthesized the deuterated analogues 6 and found that it showed higher drug exposure and thus stronger antitumor potency in preclinical settings. Compound 6 is being developed clinically for the potential to be differentiated from enzalutamide through reduced dosages and a higher safety margin.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available